We are live on ! Find out more
PTCT icon

PTC Therapeutics

125 hedge funds and large institutions have $636M invested in PTC Therapeutics in 2017 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 42 increasing their positions, 41 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

5.48% more ownership

Funds ownership: 86.37%91.86% (+5.5%)

2% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 41

8% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 26

3% less funds holding

Funds holding: 129125 (-4)

11% less capital invested

Capital invested by funds: $715M → $636M (-$79.6M)

20% less funds holding in top 10

Funds holding in top 10: 54 (-1)

81% less call options, than puts

Call options by funds: $9.17M | Put options by funds: $48M

Holders
125
Holders Change
-4
Holders Change %
-3.1%
% of All Funds
2.84%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.09%
New
24
Increased
42
Reduced
41
Closed
26
Calls
$9.17M
Puts
$48M
Net Calls
-$38.9M
Net Calls Change
+$6.04M
Name Holding Trade Value Shares
Change
Change in
Stake
DAM
126
DLD Asset Management
New York
-$12.3M -612,543 Closed
NI
127
Numeric Investors
Massachusetts
-$9.42M -470,982 Closed
Point72 Asset Management
128
Point72 Asset Management
Connecticut
-$8M -400,000 Closed
QIM
129
Quantitative Investment Management
Virginia
-$6.11M -305,100 Closed
GTC
130
Ghost Tree Capital
New York
-$2M -100,000 Closed
3C
131
361 Capital
Colorado
-$1.79M -89,600 Closed
Jane Street
132
Jane Street
New York
-$1.58M -78,768 Closed
SSA
133
Schonfeld Strategic Advisors
New York
-$1.38M -68,739 Closed
WVP
134
Worth Venture Partners
New Jersey
-$1.32M -66,196 Closed
MWNA
135
Marshall Wace North America
New York
-$1.24M -61,745 Closed
Prudential Financial
136
Prudential Financial
New Jersey
-$1.02M -51,227 Closed
SG Americas Securities
137
SG Americas Securities
New York
-$834K -41,694 Closed
SCA
138
Secor Capital Advisors
New York
-$475K -23,722 Closed
UFF
139
USA Financial Formulas
Michigan
-$465K -23,214 Closed
Canada Pension Plan Investment Board
140
Canada Pension Plan Investment Board
Ontario, Canada
-$464K -23,200 Closed
NFA
141
Nationwide Fund Advisors
Ohio
-$435K -21,718 Closed
GAM
142
Gotham Asset Management
New York
-$396K -19,796 Closed
VRS
143
Virginia Retirement Systems
Virginia
-$374K -18,700 Closed
Balyasny Asset Management
144
Balyasny Asset Management
Illinois
-$302K -15,100 Closed
Acadian Asset Management
145
Acadian Asset Management
Massachusetts
-$236K -11,762 Closed
Ohio Public Employees Retirement System (OPERS)
146
Ohio Public Employees Retirement System (OPERS)
Ohio
-$232K -11,582 Closed
Los Angeles Capital Management
147
Los Angeles Capital Management
California
-$229K -11,460 Closed
ACM
148
Advent Capital Management
New York
-$200K -10,000 Closed
CSS
149
Cubist Systematic Strategies
Connecticut
-$93K -4,662 Closed
IA
150
IFP Advisors
Florida
-$1.37K -81 -84%

PTCT Hedge Fund Activity: Q4 2017 in Review

125 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q4 2017, worth a combined $636M — down 11% from $715M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of PTCT and 24 opened new positions — a net loss of 2 holders — while 41 trimmed existing stakes and 42 added.

The largest buyer was Scopia Capital Management, adding an estimated $49.9M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $79M sold.

  • 125 institutional investors held PTC Therapeutics (PTCT) as of Q4 2017, down from 129 in Q3 2017.
  • Funds reported $636M of PTC Therapeutics stock for Q4 2017, down 11% quarter-over-quarter.
  • 24 funds opened new PTC Therapeutics positions in Q4 2017 and 26 closed out, a net change of -2 holders.
  • The largest PTC Therapeutics buyer in Q4 2017 was Scopia Capital Management, an estimated $49.9M added.
  • The largest PTC Therapeutics seller in Q4 2017 was Consonance Capital Management, an estimated $79M sold.

Based on aggregated 13F filings for Q4 2017.